Find Clinical Trials
Long term double blind comparison of gliclazide MR (30 to 120 mg daily per os) and rosiglitazone (4 to 8 mg daily per os) given in combination with metformin in type 2 diabetic patients.A 2-year international, multicentre, randomised, double-blind, parallel-group study followed by a 2-year double blind extension. – ENDORSE
Servier Protocol Code:
CL3-05702-013
Sponsor:
Institut de Recherches Internationales Servier (I.R.I.S)
EudraCT Number:
2006-001240-30
Find a recruiting site
Name:
Institut de Recherches Internationales Servier, Département des études cliniques
Phone number:
+33 1 55 72 60 00
Results
English (USA)Interventions / Treatments
The treatment(s) given to the participants in the study.
- Diabetes - Type II
- GLICLAZIDE
- S005702
Other study id numbers
Other identification numbers the study may be known by.
- CL3-05702-013